ClinicalTrials.gg
Not yet recruitingNCT07940049CovaRiskUpdated Nov 16, 2026

CovaRisk: Validating a Digital Tool for Ovarian Cancer Risk Assessment and Referral

An observational study in Cancer Ovaries, Ovarian Mass and Borderline Ovarian Cancer, sponsored by Benha University. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Benha University · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
320
Ages
18 Years and older
Sex
Female
01

Study summary

Ovarian cancer is frequently diagnosed at an advanced stage, while its early symptoms are often nonspecific . In women presenting with an adnexal mass, clinicians must integrate clinical symptoms, menopausal status, tumour markers, ultrasound findings, cross-sectional imaging, and hereditary risk when deciding whether a patient requires urgent gynaecologic oncology referral, specialist review, additional imaging, or conservative follow-up . Existing validated tools address individual components of this pathway, but these tools and guideline recommendations are distributed across different resources .

Read the detailed description

CovaRisk is an application-based clinical decision support tool designed to integrate many diagnostic elements into a stepwise assessment . It combines symptom criteria, age-adjusted CA-125 interpretation, HE4/ROMA, Risk of Malignancy Index (RMI), IOTA Simple Rules, O-RADS ultrasound and MRI classification, selected tumour markers, and hereditary risk information. The tool provides a transparent triage category and guideline-based next steps while directing users to established specialist tools where appropriate. CovaRisk is intended to support, rather than replace, clinical judgement and validated specialist models .This study aims to evaluate the diagnostic accuracy of CovaRisk version 1.0 for identifying ovarian malignancy, including borderline tumours, using final histopathology as the reference standard, and to compare its performance with the Risk of Malignancy Index and O-RADS ultrasound classification in the same cohort .This study will be a single-centre retrospective diagnostic accuracy study of women aged 18 years or older who underwent surgery for an adnexal mass and have final histopathology available. Preoperative information will be entered into the frozen CovaRisk version 1.0 without access to the postoperative histopathology result . CovaRisk classification will be compared with final histology as the reference standard. Diagnostic performance will be assessed using sensitivity, specificity, predictive values, likelihood ratios, receiver operating characteristic curves and area under the curve . CovaRisk will also be compared with RMI and O-RADS ultrasound in the same cohort .The study will provide an objective assessment of whether CovaRisk can accurately identify ovarian malignancy in a real-world hospital population. The findings will guide refinement of the tool and determine whether it is appropriate to proceed to subsequent usability testing and prospective validation.Innovation CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterisation of adnexal masses , standardised imaging risk stratification, and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population.

In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide. These features are consistent with the recognised role of clinical decision support systems in standardising care and reducing unwarranted variation in clinical decision-making .

02

Conditions studied

  • Cancer Ovaries
  • Ovarian Mass
  • Borderline Ovarian Cancer

Browse trials for

Keywords

  • Tool cancer ovary Risk RMI CovaRisk
03

In context

Ovarian Neoplasms

3,385 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

This study's planned enrollment of 320 is above the median of 200 across 616 observational studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

Benha University is the lead sponsor of 364 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women aged 18 years or older who underwent surgery for an adnexal mass at King Faisal Specialist Hospital \& Research Centre, Madinah, Saudi Arabia, between January 2021 and December 2025, and who have final histopathology available. Consecutive eligible cases are identified from operating theatre records and the institutional histopathology database. Included records contain sufficient preoperative information, at least a preoperative ultrasound report or a CA-125 result. Women with previous ovarian cancer are excluded. Data are extracted retrospectively from existing medical records; no participants are recruited or contacted.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 years or older.
  • Surgical treatment for an adnexal mass at the host institution during the defined retrospective study period.
  • Availability of final histopathology.
  • Availability of sufficient preoperative clinical information, including at least a preoperative ultrasound report and CA-125 result, according to the study eligibility definition

Exclusion criteria

Exclusion Criteria:

  • Previous ovarian cancer.

    • Absence of both a preoperative ultrasound report and CA-125 result.
    • Records in which the relevant preoperative information cannot be reliably established.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
320 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective Adnexal Mass Diagnostic Cohort

    A single retrospective cohort of women aged 18 years or older who underwent surgical treatment for an adnexal mass at King Faisal Specialist Hospital \& Research Centre, Madinah. Preoperative clinical, laboratory, imaging, and hereditary risk data are entered into the CovaRisk version 1.0 tool (blinded to final outcomes), and its diagnostic performance is evaluated against final histopathology as the reference standard, alongside comparative assessments using the Risk of Malignancy Index (RMI) and O-RADS ultrasound classification

    Other: CovaRisk is an application-based clinical decision support tool designed to integrate many diagnostic elements into a stepwise assessment [9]. It combines symptom criteria, age-adjusted CA-125 interp

  • Arm 1: CovaRisk - Diagnostic classification using the CovaRisk version 1.0 tool. Arm 2: Risk of M

    This is a retrospective diagnostic accuracy study. These are paired diagnostic assessment methods applied to the same patients, not separate groups receiving different interventions.

    Other: CovaRisk is an application-based clinical decision support tool designed to integrate many diagnostic elements into a stepwise assessment [9]. It combines symptom criteria, age-adjusted CA-125 interp

Interventions

  • OtherCovaRisk is an application-based clinical decision support tool designed to integrate many diagnostic elements into a stepwise assessment [9]. It combines symptom criteria, age-adjusted CA-125 interp

    CovaRisk does not introduce a new biomarker or imaging sign; its innovation lies in integration and implementation. Validated tools currently address separate stages of the diagnostic pathway: CA-125 and age-based triage in primary care , ultrasound characterization of adnexal masses , standardized imaging risk stratification , and hereditary breast and ovarian cancer risk estimation . To our knowledge, CovaRisk is the first tool to integrate symptom-based, laboratory, imaging and hereditary risk assessment for suspected ovarian cancer into a single, transparent, guideline-based triage pathway , and this study will be the first to validate such an integrated tool in a Saudi population. In addition to measuring diagnostic accuracy, comparison of CovaRisk recommendations with the pathways actually followed will provide an audit of adherence to guideline-based referral and genetic counselling , information that single-score calculators do not provide.

    Also known as: CovaRisk, TOOL

06

What researchers measure

Primary outcomes

  1. Sensitivity of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy, Including Borderline Tumors, Against Final Histopathology

    Proportion of women with a histologically confirmed malignant or borderline ovarian tumour who are classified as high-risk by CovaRisk v1.0. CovaRisk is applied to preoperative data already recorded in medical records, without knowledge of the histopathology result. Reported as a percentage with 95% confidence interval.

    Time frame: Single retrospective record review of surgeries performed January 2021 to December 2025

  2. Specificity of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy Against Final Histopathology

    •Proportion of women with benign final histopathology who are classified as not high-risk (intermediate, low or information-only) by CovaRisk v1.0. Reported as a percentage with 95% confidence interval.

    Time frame: Single retrospective record review of surgeries performed January 2021 to December 2025

Secondary outcomes

  1. Positive Predictive Value of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy

    Proportion of women classified as high-risk by CovaRisk v1.0 who have malignant or borderline final histopathology, with 95% confidence interval. Unit: percentage of participants

    Time frame: Single retrospective record review of surgeries performed January 2021 to December 2025.

  2. Negative Predictive Value of CovaRisk v1.0 High-Risk Triage for Ovarian Malignancy

    Proportion of women not classified as high-risk by CovaRisk v1.0 who have benign final histopathology, with 95% confidence interval. Unit: percentage of participants

    Time frame: Single retrospective record review of surgeries performed January 2021 to December 2025

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L, Cibula D, Concin N, Fischerova D, Froyman W, Gallardo Madueno G, Lemley B, Loft A, Mereu L, Morice P, Querleu D, Testa AC, Vergote I, Vandecaveye V, Scambia G, Fotopoulou C. ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. Int J Gynecol Cancer. 2021 Jul;31(7):961-982. doi: 10.1136/ijgc-2021-002565. Epub 2021 Jun 10. PubMed 34112736 ↗
  • Sadowski EA, Thomassin-Naggara I, Rockall A, Maturen KE, Forstner R, Jha P, Nougaret S, Siegelman ES, Reinhold C. O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee. Radiology. 2022 Apr;303(1):35-47. doi: 10.1148/radiol.204371. Epub 2022 Jan 18. PubMed 35040672 ↗
  • American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol. 2016 Nov;128(5):e210-e226. doi: 10.1097/AOG.0000000000001768. PubMed 27776072 ↗
  • Royal College of Obstetricians and Gynaecologists. The management of ovarian cysts in postmenopausal women. Green-top Guideline No. 34. London: RCOG; 2016
  • Royal College of Obstetricians and Gynaecologists. Management of suspected ovarian masses in premenopausal women. Green-top Guideline No. 62. London: RCOG; 2011.
  • National Collaborating Centre for Cancer (UK). Suspected Cancer: Recognition and Referral. London: National Institute for Health and Care Excellence (NICE); 2015 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK304993/ PubMed 26180880 ↗
  • Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29. PubMed 29809280 ↗

Individual participant data

Plan to share: No — The document primarily notes that research data will be stored securely on password-protected institutional systems and accessible only to authorized members of the research team in compliance with data-protection requirements.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jan 2028, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jun 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940049
Lead sponsor
Benha University
Collaborators
King Faisal Specialist Hospital & Research Center
Responsible party
Ahmed Kamal Eldin Abbas Attia (ASCOCIATE PROFESSOR, Benha University) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jan 1, 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

AHMED KAMALELDIN ATTIA, ASCOCIATE PROFESSOR
Contact
dr.ahmed.attia2021@gmail.com
+966573667477
Mohamed Hassan Mohamed, Assistant Professor
Contact
M_hassan@med.suez.edu.eg
+966573667609

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion